title: An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types.
abstract: Wiskott-Aldrich syndrome (WAS) predisposes patients to leukemia and lymphoma. WAS is caused by mutations in the protein WASP which impair its interaction with the WIPF1 protein. Here, we aim to identify a module of WIPF1-coexpressed genes and to assess its use as a prognostic signature for colorectal cancer, glioma, and breast cancer patients. Two public colorectal cancer microarray data sets were used for discovery and validation of the WIPF1 co-expression module. Based on expression of the WIPF1 signature, we classified more than 400 additional tumors with microarray data from our own experiments or from publicly available data sets according to their WIPF1 signature expression. This allowed us to separate patient populations for colorectal cancers, breast cancers, and gliomas for which clinical characteristics like survival times and times to relapse were analyzed. Groups of colorectal cancer, breast cancer, and glioma patients with low expression of the WIPF1 co-expression module generally had a favorable prognosis. In addition, the majority of WIPF1 signature genes are individually correlated with disease outcome in different studies. Literature gene network analysis revealed that among WIPF1 co-expressed genes known direct transcriptional targets of c-myc, ESR1 and p53 are enriched. The mean expression profile of WIPF1 signature genes is correlated with the profile of a proliferation signature. The WIPF1 signature is the first microarray-based prognostic expression signature primarily developed for colorectal cancer that is instrumental in other tumor types: low expression of the WIPF1 module is associated with better prognosis.
authors.affiliation: Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany. eike.staub@nucleolus.net
authors.forename: Eike
authors.initials: E
authors.lastname: Staub
authors.forename: Joern
authors.initials: J
authors.lastname: Groene
authors.forename: Maya
authors.initials: M
authors.lastname: Heinze
authors.forename: Detlev
authors.initials: D
authors.lastname: Mennerich
authors.forename: Stefan
authors.initials: S
authors.lastname: Roepcke
authors.forename: Irina
authors.initials: I
authors.lastname: Klaman
authors.forename: Bernd
authors.initials: B
authors.lastname: Hinzmann
authors.forename: Esmeralda
authors.initials: E
authors.lastname: Castanos-Velez
authors.forename: Christian
authors.initials: C
authors.lastname: Pilarsky
authors.forename: Benno
authors.initials: B
authors.lastname: Mann
authors.forename: Thomas
authors.initials: T
authors.lastname: Brümmendorf
authors.forename: Birgit
authors.initials: B
authors.lastname: Weber
authors.forename: Heinz-Johannes
authors.initials: HJ
authors.lastname: Buhr
authors.forename: André
authors.initials: A
authors.lastname: Rosenthal
mesh_terms: D017209:Apoptosis; D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000235:genetics; D003598:Cytoskeletal Proteins / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling; D053263:Gene Regulatory Networks; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics; D011379:Prognosis; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D051317:Wiskott-Aldrich Syndrome Protein, Neuronal / Q000235:genetics / Q000378:metabolism
chemical_list: D003598:Cytoskeletal Proteins; D047908:Intracellular Signaling Peptides and Proteins; C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc; D016159:Tumor Suppressor Protein p53; C109903:WIPF1 protein, human; D051317:Wiskott-Aldrich Syndrome Protein, Neuronal